AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00965900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EBL+Propranolol
Description: 1. EBL~   * Perform EBL within 7 days after randomization~  * Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~  * Acid suppression using proton pump inhibitor until eradicated.~  * After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).~2. Propranolol~   * start with 20 mg b.i.d~  * Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~  * After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)
Study NCT02370888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Subjects will be enrolled in cohorts of three (3). Lenalidomide will be administered for 21 consecutive days in a 28 day cycle X 2 cycles. The starting dose will be 2.5 mg given orally every other day for 21 days.
Study NCT00359762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection (5mcg or 10mcg), twice a day
Study NCT00359762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: oral tablet (titrated to maximally tolerated dose), once daily
Study NCT00621439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interfon Alpha 2B
Description: Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.
Study NCT00621439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo.
Study NCT01785524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beetroot Juice (Beet-It Stamina Shot) and Exercise Training
Description: The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
Study NCT01785524 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training
Description: The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
Study NCT02778529 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bilateral assessment robots (BiAS)
Description: The BiAS are two passive desktop robots that will be used in this study to measure right and left arm kinematics for 4 different groups of patients.
Study NCT03147105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: arm ergometry
Description: home based arm ergometry, at least 4-5 sessions/week for 12 weeks
Study NCT03147105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: arm ergometry
Description: home based arm ergometry, at least 4-5 sessions/week for 12 weeks
Study NCT04168749 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Numeta G13
Description: 10 days
Study NCT02956629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.
Study NCT02956629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.
Study NCT03430609 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ultrasound for antral follicle count
Description: The participants will be subjected to transvaginal ultrasound for antral follicle count before surgery (1 month before surgery) and 1, 3 and 6 months after surgery. This test will be performed during the early proliferative stage (days 3 to 6 of the menstrual cycle); the size of the endometrioma and the ovary volume will be recorded, and functional cysts or suspected malignant cysts will be ruled out. For measurement of cysts, the average diameter of the three perpendicular ovary dimensions will be considered. For antral follicle count, the total number of follicles with diameters under 9 mm will be considered.
Study NCT02956629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.
Study NCT01983800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Study NCT01983800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol/midazolam
Study NCT02202135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Description: IV ceftaroline 600mg every 8 hours
Study NCT02202135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: IV vancomycin 15mg/kg every 12 hours
Study NCT02202135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam
Description: IV aztreonam 1 g every 8 hours
Study NCT02148094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: The demonstration project will use a prospective cohort design, enrolling individuals and following them up at multiple intervals over the course of 16 months. Study participants will be asked to take one tablet of Truvada daily, as HIV Pre-Exposure Prophylaxis, over this period. They will be asked to attend 7 regular visits at the project sites over the course of the project. In between visits, they will receive peer educator home visits every other day, as part of regular DMSC (Kolkata) and Ashodaya (Mysore/Mandya) outreach prevention activities. We plan to enroll 2000 female sex workers equally split between the two sites.
Study NCT00129415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UVA1 Irradiation
Description: The affected areas on the body will be treated with UVA1 (Sellemed UVA1 light source) for up to 5 times per week for 16 weeks. The UVA1 dose will be up to 130 J/cm2.
Study NCT00129415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UVB Irradiation
Description: The affected areas on the body will be treated with UVB light for up to 5 times per week for 16 weeks. The maximum UVB dose will be 4000 mJ/cm2.
Study NCT01083550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid exposure
Description: Exposure to a computerized decision aid on adjuvant radioactive iodine treatment decision-making. The exposure is during one visit.
Study NCT02360917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emerging from the Haze
Description: A 6 week psycho-educational class
Study NCT02360917 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Emerging from the Haze
Description: A 6 week psycho-educational class
Study NCT03888313 — intervention group
Intervention type: OTHER
Intervention: Pretreatment group consultation
Description: A consultation in group with several patients and one surgeon
Study NCT03264625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (2000iu qd)
Description: Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
Study NCT03264625 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine therapy for PD
Description: Patients randomized to the placebo group will receive routine therapy for PD.
Study NCT03264625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine therapy for PD
Description: Patients randomized to the placebo group will receive routine therapy for PD.
Study NCT01316627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crooked Mirror Externalization Therapy
Description: After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
Study NCT01316627 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Retraining Method
Description: After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
Study NCT04978246 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychometric Test
Description: Participants' global cognitive skills were measured by the Montreal Cognitive Assessment Test (MoCA), the Clock Drawing Test and memory functions, the Öktem Verbal Memory Processes Test (Ö-SBST), the attention functions by the Digit Span Forward and Digit Span Backwards Test, the executive functions by Categorical Fluency, Phonemic Fluency, the Stroop Test, Trail Making Test A and B, visuospatial skills were evaluated with the Rey-Osterrieth Complex Figure Test (ROCF), and behavioral symptoms were evaluated with the Neuropsychiatric Inventory (NPI).
Study NCT01790750 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PES first, then FFES
Description: A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
Study NCT01263873 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mallinckrodt (ETT)
Description: 7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
Study NCT01263873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip (ETT)
Description: 7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
Study NCT02097875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLZ-100
Study NCT02461589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.
Study NCT02461589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.
Study NCT02461589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously ( s.c., under the skin) once daily.
Study NCT03690206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glepaglutide
Description: Glucagon-Like Peptide-2 (GLP-2) analog
Study NCT03690206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for glepaglutide
Study NCT03690206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for glepaglutide
Study NCT01903213 — intervention group
Intervention type: DRUG
Intervention: bixalomer
Description: Oral
Study NCT02842086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: 200/25 mg tablet administered orally once daily
Study NCT02842086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TDF
Description: 200/300 mg tablet administered orally once daily
Study NCT02842086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF Placebo
Description: Tablet administered orally once daily
Study NCT02842086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TDF Placebo
Description: Tablet administered orally once daily
Study NCT03847428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous)
Study NCT03430609 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic treatment for endometrioma Vicryl®
Description: Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will perform suture with 2-0 Vicryl® in this group.
Study NCT03430609 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic treatment for endometrioma Surgicel®
Description: Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In this group, for hemostasis , the investigators will use matrix Surgicel®
Study NCT03847428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab IV (intravenous)
Study NCT03847428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous) or Dextrose for Durvalumab masking
Study NCT04203719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105
Description: AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
Study NCT03847428 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous) or Dextrose for Durvalumab masking
Study NCT04203719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor
Study NCT04219956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyamine Deficient Diet
Description: Diet low in polyamines: the estimated calculated dose is 20 times lower that in an usual diet
Study NCT04328311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watermelon Juice
Description: 500 mL watermelon juice (What a Melon), containing \~1 g of L-citrulline.
Study NCT04328311 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: 500 mL low nitrate water
Study NCT00982189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Participants randomized to take pravastatin (active) or matching placebo pill once daily
Study NCT00982189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pravastatin
Description: Participants randomized to take pravastatin (active) or matching placebo pill once daily
Study NCT00982189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Participants randomized to take lisinopril (active) or matching placebo pill once daily
Study NCT00982189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lisinopril
Description: Participants randomized to take lisinopril (active) or matching placebo pill once daily
Study NCT01504789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Fitness Test
Description: Complete fitness tests to measure strength, flexibility, balance, and aerobic capacity. All of the baseline fitness tests will be repeated at the end of the program (at about the 16th week) during a follow-up visit.
Study NCT01504789 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Fitness Test
Description: Complete fitness tests to measure strength, flexibility, balance, and aerobic capacity. All of the baseline fitness tests will be repeated at the end of the program (at about the 16th week) during a follow-up visit.
Study NCT01504789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: At the baseline visit, complete questionnaires about demographic information taking about 35 minutes to complete. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. It should take about 10 minutes to complete these questionnaires. Patients also be asked to fill out a questionnaire every week that asks about level of physical activity. The questionnaire should take about 5 minutes to complete.
Study NCT01504789 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: At the baseline visit, complete questionnaires about demographic information taking about 35 minutes to complete. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. It should take about 10 minutes to complete these questionnaires. Patients also be asked to fill out a questionnaire every week that asks about level of physical activity. The questionnaire should take about 5 minutes to complete.
Study NCT01504789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Exercise Program
Description: The exercise programs will be individualized based on results from baseline fitness assessments and individual medical history using ACSM guidelines. For resistance and flexibility exercises each patient will receive an exercise prescription and instructional session prior to beginning the program. Invitation extended to attend monthly Group Exercise sessions with a family member. Resistance tubes, pedometer, exercise book, and video issued for use at home.
Study NCT01504789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Materials
Description: Either culturally adapted AI materials or non-culturally intervention materials will be mailed to patients every 2 weeks. The 7 themed sessions are: Getting Started;Goal Setting;Effective Energy Balance;Getting Confident;Uncovering Barriers;Lapsing, Relapsing, Collapsing;and Continuing to be Active.
Study NCT03004963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body composition monitor
Description: Both body composition monitor (BCM) is used to evaluate the volume status of patients.
Study NCT03004963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: clinical indexes
Description: The investigators evaluate the volume status of patients according to clinical indexes.
Study NCT03004963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: clinical indexes
Description: The investigators evaluate the volume status of patients according to clinical indexes.
Study NCT04475445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transforaminal epidural steroid injection
Description: Ultrasound identification of the nerve root, fluoroscopic control of the position and injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
Study NCT04475445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interlaminar epidural steroid injection
Description: Fluoroscopic location of the epidural space C5C6 or C6C7, injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
Study NCT00956150 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lactulose Breath Test
Description: Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
Study NCT00956150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Breath Test
Description: Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
Study NCT00956150 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lactulose Breath Test
Description: Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
Study NCT00956150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 600 mg three times a day by mouth (TID PO) x 10 days
Study NCT00956150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo TID PO x 10 days